HIGH END CELLOMICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

High End Cellomics Market, By Product Type (Instruments, Reagents and Consumables, and Software & Services), By Application (Drug discovery, Cancer Research, Neuroscience, Stem Cell Research and Regenerative Medicine, Personalized Medicine, and Others), By Technology (Microscopy, Flow Cytometry, Single-cell Genomics, Mass Spectrometry, Next Generation Sequencing, and Others), By End User (Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

High End Cellomics Market Regional Insights:

North America is expected to be the largest market for high end cellomics during the forecast period, accounting for over 40.5% of the market share in 2023. The growth of the market in North America is attributed to high healthcare expenditure, presence of key players, and growing research on cellomics. For instance, in June 2021, Thermo Fisher Scientific Inc., a major biotechnology company based in the U.S., announced the launch of the Invitrogen Attune CytPix Flow Cytometer, an imaging-enhanced flow cytometer that combines acoustic focusing flow cytometry technology with a high-speed camera. The Attune CytPix collects high-performance fluorescent flow cytometry data from cells while also recording high resolution brightfield images, allowing users to match images with flow cytometry data to better understand the morphology and quality of the cells.
Europe market is expected to be the second largest market for high end cellomics, accounting for over 28.7% of the market share in 2023. The growth of the market in Europe is attributed to increasing research funding and rising incidence of chronic diseases.
Asia Pacific market is expected to be the fastest-growing market for high end cellomics, with a CAGR of over 15% during the forecast period. The growth of the market in Asia Pacific is attributed to the improving healthcare infrastructure, growing biopharma sector, and increasing focus on precision medicine.